Literature DB >> 21840673

In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp.

Tarcieli P Venturini1, Luana Rossato, Tatiana B Spader, Giordano R Tronco-Alves, Maria Izabel Azevedo, Caroline B Weiler, Janio M Santurio, Sydney Hartz Alves.   

Abstract

Fusarium spp is an opportunistic fungal pathogen responsible for causing invasive hyalohyphomycosis in immunocompromised patients. Due to its susceptibility pattern with a remarkable resistance to antifungal agents the treatment failures and mortality rates are high. To overcome this situation, combination therapy may be considered which must be subjected to in vitro tests. In vitro activities of amphotericin B, itraconazole, and voriconazole associated with azithromycin, ciprofloxacin, fluvastatin, ibuprofen, metronidazole, and also the combination of amphotericin B plus rifampin against 23 strains of Fusarium spp. through the checkerboard technique based on M38-A2 [Clinical and Laboratory Standards Institute (2008). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. (CLSI document M38-A2) (ISBN 1-56238-668-9). Wayne, PA: CLSI] were evaluated. The best synergistic interactions with amphotericin B were with ibuprofen (43.5%) (FICI [fractional inhibitory concentration index] range = 0.25-2). Combinations with voriconazole showed synergism, mainly with ciprofloxacin (30.4%) (FICI range = 0.25-3) and metronidazole (30.4%) (FICI range = 0.1-4); however, all the combinations with itraconazole were indifferent. In general, antagonistic interactions were not registered. Our results showed that in vitro synergisms obtained by some combinations studied deserve attention since they were better than those showed by the antimycotic.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840673     DOI: 10.1016/j.diagmicrobio.2011.05.007

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

1.  Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.

Authors:  Sofia Costa-de-Oliveira; Isabel M Miranda; Ana Silva-Dias; Ana P Silva; Acácio G Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

Review 2.  Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients.

Authors:  Frederic Lamoth; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

3.  Anti-Sporothrix activity of ibuprofen combined with antifungal.

Authors:  Luana Pereira Borba-Santos; Marcio Nucci; Antonio Ferreira-Pereira; Sonia Rozental
Journal:  Braz J Microbiol       Date:  2020-07-02       Impact factor: 2.476

Review 4.  Molecular targets of statins and their potential side effects: Not all the glitter is gold.

Authors:  Kush K Patel; Viren S Sehgal; Khosrow Kashfi
Journal:  Eur J Pharmacol       Date:  2022-03-20       Impact factor: 4.432

5.  Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin.

Authors:  Rita Teixeira-Santos; Elisabete Ricardo; Ricardo J Branco; Maria M Azevedo; Acácio G Rodrigues; Cidália Pina-Vaz
Journal:  Front Microbiol       Date:  2016-09-13       Impact factor: 5.640

Review 6.  Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal.

Authors:  Sofia Costa-de-Oliveira; Acácio G Rodrigues
Journal:  Microorganisms       Date:  2020-01-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.